APA (7th ed.) Citation

M, M., FA, H., B, E., S, D., B, M., H, I., . . . A, C. (2017). Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology, 18(12), 1688. https://doi.org/10.1016/S1470-2045(17)30717-9

Chicago Style (17th ed.) Citation

M, Martin, et al. "Neratinib After Trastuzumab-based Adjuvant Therapy in HER2-positive Breast Cancer (ExteNET): 5-year Analysis of a Randomised, Double-blind, Placebo-controlled, Phase 3 Trial." The Lancet. Oncology 18, no. 12 (2017): 1688. https://doi.org/10.1016/S1470-2045(17)30717-9.

MLA (9th ed.) Citation

M, Martin, et al. "Neratinib After Trastuzumab-based Adjuvant Therapy in HER2-positive Breast Cancer (ExteNET): 5-year Analysis of a Randomised, Double-blind, Placebo-controlled, Phase 3 Trial." The Lancet. Oncology, vol. 18, no. 12, 2017, p. 1688, https://doi.org/10.1016/S1470-2045(17)30717-9.